GFAP and amyloidosis: 3xTg mice were injected at 3–4 months with AAV-GFP or AAV-SOCS3 + AAV-GFP (3xTg-GFP and 3xTg-SOCS3 mice respectively) and studied 5 months later, when they display synaptic deficits and higher GFAP levels [11, 53] but before amyloid plaque and Tau deposition ([59], Fig. 6a).